Effects of zoledronic acid (ZOL) on proliferation of nasopharyngeal carcinoma (NPC) cell lines and synergistic effects of ZOL and cisplatin on NPC cell lines.
Sub-category: Cytotoxic Chemotherapy
Category: Developmental Therapeutics: Cytotoxic Chemotherapy
Meeting: 2009 ASCO Annual Meeting
Citation: J Clin Oncol 27, 2009 (suppl; abstr e13536)
Abstract No: e13536
| | New this year -- Publication-only abstracts (abstract number preceded by an 'e'), are published in conjunction with the 2009 Annual Meeting but not presented at the Meeting, can be found online only.
The publication-only abstracts are not included in the print or CD versions of the ASCO Annual Meeting Proceedings Part I, but they are citable to this issue of the Journal of Clinical Oncology as a supplement (see citation on left).
|
Personalize your Annual Meeting experience with a suggested or customized itinerary!
 |
|
Author(s): B. R. Ghimire; Om Hospital and Research Centre, Kathmandu, Nepal
Abstract:
Background: Recent evidence suggests that zoledronic acid (ZOL) inhibits cancer cell proliferation and exerts synergistic antitumor activity at clinically achievable concentrations and have shown the potential to become attractive agents for cancer therapy. This study is the first to report the effects of ZOL on NPC cell lines.
Methods: Cell proliferations were determined by MTT assay on four NPC cell lines CNE-1, CNE-2, SUNE-1 and 5-8F. NPC cell lines were seeded in a flat-bottomed 96well plate at 10
+4 in 200µl of medium per well and incubated with various concentrations of ZOL for 72 hours. IC
50 values for each cell lines were obtained using the non-linear regression program CalcuSyn. IC
10 values for ZOL and Cisplatin were calculated from the IC
50 curve of each four cell lines. For displaying the synergistic activity concentration equivalent to IC
10 of ZOL alone, Cisplatin alone and in combination were added. The entire specimen was incubated for a total of 72 hours and the absorbance was measured at a wavelength of 540nm in a multiwell spectrophotometer.
Results: IC5O values (µM) of ZOL on NPC cell lines SUNE-1, CNE-1, CNE-2, 5-8F were 4.56±0.09, 11.96±0.50, 16.73±0.28, 11.01±0.64 respectively.
Conclusions: The experiment establishes synergistic effects of ZOL and cisplatin in anti proliferation of NPC cell lines. Thus, ZOL in combination with other cytotoxic agents may be promising therapeutic strategies for NPC with bone metastasis. The efficacy and safety of ZOL for NPC should be verified in early phase clinical trials
Inhibition of proliferation (%) when ZOL and cisplatin used alone and in combination
|
| Cell lines | Concentration of
drugs used ZOL(µM)
and cisplatin (µM)
respectively | Combination
of ZOL and
cisplatin | ZOL alone | Cisplatin alone |
|
| SUNE-1 | 0.9 and 0.4 | 63.33±3.02% | 13.44±8.02% | 14.36±8.67% |
| CNE-1 | 2.8 and 0.41 | 63.95±5.5% | 13.61±6.96% | 13.61±5.33% |
| CNE-2 | 3 and 0.8 | 42.29±1.96% | 14.30±3.00% | 14.93±2.37% |
| 5-8F | 2.2 and 0.5 | 60.61±7.5% | 10.37±5.8% | 11.35±6.8% |
|